Anticancer properties of zoledronic acid

Cancer Investigation

Volumn 28, Issue 9, 2010, Pages 944-957

  Green, Jonathan ^a   Lipton, Allan ^b  

^a Preclinical Research   (Switzerland)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Breast cancer; Invasion and metastasis; Zoledronic acid

Indexed keywords

ANASTROZOLE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GEFITINIB; GEMCITABINE; GOSERELIN; IBANDRONIC ACID; LETROZOLE; MELPHALAN; PACLITAXEL; PREDNISONE; TAMOXIFEN; THALIDOMIDE; VINCRISTINE; ZOLEDRONIC ACID;

ADD ON THERAPY; ADJUVANT THERAPY; ANDROGEN DEPRIVATION THERAPY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST CARCINOMA; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER MODEL; CANCER PATIENT; CANCER SURVIVAL; CELL ADHESION; CELL CYCLE ARREST; CELL INVASION; CELL PROLIFERATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; DISEASE FREE SURVIVAL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DRUG TISSUE LEVEL; DRUG UPTAKE; EARLY CANCER; HUMAN; IC 50; IMMUNOMODULATION; IMMUNOSURVEILLANCE; IN VITRO STUDY; LEWIS CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MACROPHAGE FUNCTION; MESOTHELIOMA; METASTASIS INHIBITION; MOLECULAR MECHANICS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TUMOR CELL; UTERINE CERVIX CARCINOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE DENSITY CONSERVATION AGENTS; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; HUMANS; IMIDAZOLES; NEOPLASMS;

EID: 77957977187     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.512598     Document Type: Review

References (91)

1. Zometa [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009
2. Rosen, L. S.; Gordon, D.; Tchekmedyian, S.; Yanagihara, R.; Hirsh, V.; Krzakowski, M.; Pawlicki, M.; de Souza, P.; Zheng, M.; Urbanowitz, G.; Reitsma, D.; Seaman, J. J. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the zoledronic acid lung cancer and other solid tumors study group. J Clin Oncol 2003, 21, 3150-3157.
3. Rosen, L. S.; Gordon, D.; Tchekmedyian, N. S.; Yanagihara, R.; Hirsh, V.; Krzakowski, M.; Pawlicki, M.; De Souza, P.; Zheng, M.; Urbanowitz, G.; Reitsma, D.; Seaman, J. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung cancer and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004, 100, 2613-2621.
4. Green, J. R. Bisphosphonates: preclinical review. Oncologist 2004. 9 (suppl 4), S3-S13.
5. Hirbe, A. C.; Roelofs, A. J.; Floyd, D. H.; Deng, H.; Becker, S. N.; Lanigan, L. G.; Apicelli, A. J.; Xu, Z.; Prior, J. L.; Eagleton, M. C.; Piwnica-Worms, D.; Rogers, M. J.; Weilbaecher, K. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 2009, 44, 908-916.
6. Hiraga, T.; Williams, P. J.; Ueda, A.; Tamura, D.; Yoneda, T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004, 10, 4559-4567.
7. Giraudo, E.; Inoue, M.; Hanahan, D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004, 114, 623-633.
8. Matsumoto, S.; Kimura, S.; Segawa, H.; Kuroda, J.; Yuasa, T.; Sato, K.; Nogawa, M.; Tanaka, F.; Maekawa, T.; Wada, H. Efficacy of the third-generation bisphosphonate, zoledronic acid alone and combined with anti-cancer agents against small cell lung cancer cell lines. Lung Cancer 2005, 47, 31-39.
9. Ory, B.; Heymann, M. F.; Kamijo, A.; Gouin, F.; Heymann, D.; Redini, F. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer 2005, 104, 2522-2529.
10. Wakchoure, S.; Merrell, M. A.; Aldrich, W.; Millender-Swain, T.; Harris, K. W.; Triozzi, P.; Selander, K. S. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res 2006, 12, 2862-2868.
11. Melani, C.; Sangaletti, S.; Barazzetta, F. M.; Werb, Z.; Colombo, M. P. Amino-bisphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 2007, 67, 11438-11446.
12. Stathopoulos, G. T.; Moschos, C.; Loutrari, H.; Kollintza, A.; Psallidas, I.; Karabela, S.; Magkouta, S.; Zhou, Z.; Papiris, S. A.; Roussos, C.; Kalomenidis, I. Zoledronic acid is effective against experimental malignant pleural effusion. Am J Respir Crit Care Med 2008, 178, 50-59.
13. Bäckman, U.; Svensson, A.; Christofferson, R. H.; Azarbayjani, F. The bisphosphonate, zoledronic acid reduces experimental neuroblastoma growth by interfering with tumor angiogenesis. Anticancer Res 2008, 28, 1551-1557.
14. Li, Y. Y.; Chang, J. W. C.; Chou, W. C.; Liaw, C. C.; Wang, H. M.; Huang, J. S.; Wang, C. H.; Yeh, K. Y. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer 2008, 59, 180-191.
15. Ottewell, P. D.; Mönkkönen, H.; Jones, M.; Lefley, D. V.; Coleman, R. E.; Holen, I. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst 2008, 100, 1167-1178.
16. Lu, S.; Zhang, J.; Zhou, Z.; Liao, M. L.; He, W. Z.; Zhou, X. Y.; Li, Z. M.; Xiang, J. Q.; Wang, J. J.; Chen, H. Q. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. Oncol Rep 2008, 20, 581-587.
17. Chang, J. W. C.; Hsieh, J. J.; Shen, Y. C.; Yeh, K. Y.; Wang, C. H.; Li, Y. Y.; Hsu, T. Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells. Cancer Lett 2009, 278, 17-26.
18. Coscia, M.; Quaglino, E.; Iezzi, M.; Curcio, C.; Pantaleoni, F.; Riganti, C.; Holen, I.; Mönkkönen, H.; Boccadoro, M.; Forni, G.; Musiani, P.; Bosia, A.; Cavallo, F.; Massaia, M. Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2009 Oct. 10 [Epub ahead of print]
19. Ottewell, P. D.; Lefley, D. V.; Cross, S. S.; Evans, C. A.; Coleman, R. E.; Holen, I. Sustained inhibition of tumor growth and prolonged survival following sequential administration of doxorubicin and zoledronic acid in a breast cancer model. Int J Cancer 2009, 126, 522-532.
20. Mundy, G. R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2, 584-593.
21. Zarogoulidis, K.; Boutsikou, E.; Zarogoulidis, P.; Eleftheriadou, E.; Kontakiotis, T.; Lithoxopoulou, H.; Tzanakakis, G.; Kanakis, I.; Karamanos, N. K. The impact of zoledronic aid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009, 125, 1705-1709.
22. Avilés, A.; Nambo, M. J.; Neri, N.; Castañeda, C.; Cleto, S.; Huerta-Guzmán, J. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007, 24, 227-230.
23. Gnant, M.; Mlineritsch, B.; Schippinger, W.; Luschin-Ebengreuth, G.; Pöstlberger, S.; Menzel, C.; Jakesz, R.; Seifert, M.; Hubalek, M.; Bjelic-Radisic, V.; Samonigg, H.; Tausch, C.; Eidtmann, H.; Steger, G.; Kwasny, W.; Dubsky, P.; Fridrik, M.; Fitzal, F.; Stierer, M.; Rücklinger, E.; Greil, R. ABCSG-12 Trial Investigators; Marth, C. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 2009, 360, 679-691.
24. Legay, F.; Gauron, S.; Deckert, F.; Gosset, G.; Pfaar, U.; Ravera, C.; Wiegand, H.; Schran, H. Development and validation of a highly sensitive RIA for zoledronic acid, a new potent heterocyclic bisphosphonate, in human serum, plasma and urine. J Pharm Biomed Anal 2002, 30, 897-911.
25. Leu, C. T.; Luegmayr, E.; Freedman, L. P.; Rodan, G. A.; Reszka, A. A. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. Bone 2006, 38, 628-36.
26. Chen, T.; Berenson, J.; Vescio, R.; Swift, R.; Gilchick, A.; Goodin, S.; LoRusso, P.; Ma, P.; Ravera, C.; Deckert, F.; Schran, H.; Seaman, J.; Skerjanec, A. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002, 42, 1228-1236.
27. Weiss, H. M.; Pfaar, U.; Schweitzer, A.; Wiegand, H.; Skerjanec, A.; Schran, H. Biodistribution and plasma protein binding of zoledronic acid. Drug Metab Dispos 2008, 36, 2043-2049.
28. Nancollas, G. H.; Tang, R.; Phipps, R. J.; Henneman, Z.; Gulde, S.; Wu, W.; Mangood, A.; Russell, R. G.; Ebetino, F. H. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006, 38, 617-627.
29. Roelofs, A. J.; Jauhiainen, M.; Mönkkönen, H.; Rogers, M. J.; Mönkkönen, J.; Thompson, K. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol. 2009, 144, 245-250.
30. Thompson, K.; Rogers, M. J.; Coxon, F. P.; Crockett, J. C. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006, 69, 1624-1632.
31. Winter, M. C.; Holen, I.; Coleman, R. E. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev 2008, 34, 453-475.
32. Gober, H. J.; Kistowska, M.; Angman, L.; Jenö, P.; Mori, L.; De Libero, G. Human T cell receptor gamma delta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003, 197, 163-168.
33. Martino, A.; Poccia, F. Gamma delta T cells and dendritic cells: close partners and biological adjuvants for new therapies. Curr Mol Med 2007, 7, 658-673.
34. Benzaid, I.; Mönkkönen, H.; Stresing, V.; Bonnelye, E.; Green, J.; Mönkkönen, J.; Touraine, J.; Clézardin, P. Zoledronic acid-induced IPP/Apppl (phosphoantigen) accumulation in human breast cancer cells correlates with Vgamma9Vdelta2 T-cell mediated cancer cell death in vitro and in vivo [abstract S9]. Bone 2010, 47: S266-S267.
35. Räikkönen, J.; Crockett, J. C.; Rogers, M. J.; Mönkkönen, H.; Auriola, S.; Mönkkönen, J. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol 2009, 157, 427-435.
36. Stresing, V.; Daubiné, F.; Benzaid, I.; Mönkkönen, H.; Clézardin, P. Bisphosphonates in cancer therapy. Cancer Lett 2007, 257, 16-35.
37. Dunford, J. E.; Thompson, K.; Coxon, F. P.; Luckman, S. P.; Hahn, F. M.; Poulter, C. D.; Ebetino, F. H.; Rogers, M. J. Structure-activity relationships for inhibition of farnesyl disphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296, 235-242.
38. Dunford, J. E.; Kwaasi, A. A.; Rogers, M. J.; Barnett, B. L.; Ebetino, F. H.; Russell, R. G.; Oppermann, U.; Kavanagh, K. L. Structureactivity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem 2008, 51, 2187-2195.
39. Guo, R. T.; Cao, R.; Liang, P. H.; Ko, T. P.; Chang, T. H.; Hudock, M. P.; Jeng, W. Y.; Chen, C. K.; Zhang, Y.; Song, Y.; Kuo, C. J.; Yin, F.; Oldfield, E.; Wang, A. H. Bisphosphonates target multiple sites in both cis-and trans-prenyltransferases. Proc Natl Acad Sci U S A 2007, 104, 10022-10027.
40. Bivi, N.; Romanello, M.; Harrison, R.; Clarke, I.; Hoyle, D. C.; Moro, L.; Ortolani, F.; Bonetti, A.; Quadrifoglio, F.; Tell, G.; Delneri, D. Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection. Genome Biol 2009, 10, R93.
41. Mönkkönen, H.; Kuokkanen, J.; Holen, I.; Evans, A.; Lefley, D. V.; Jauhiainen, M.; Auriola, S.; Mönkkönen, J. Bisphosphonateinduced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 2008, 19, 391-399.
42. Fromigue, O.; Lagneaux, L.; Body, J. J. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res 2000, 15, 2211-2221.
43. Senaratne, S. G.; Pirianov, G.; Mansi, J. L.; Arnett, T. R.; Colston, K. W. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000, 82, 1459-1468.
44. Jagdev, S. P.; Coleman, R. E.; Shipman, C. M.; Rostami, H. A.; Croucher, P. I. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001, 84, 1126-1134.
45. Verdijk, R.; Franke, H. R.; Wolbers, F.; Vermes, I. Differential effects of bisphosphonates on breast cancer cell lines. Cancer Lett 2007, 246, 308-312.
46. Ullén, A.; Schwarz, S.; Lennartsson, L.; Kalkner, K. M.; Sandstrom, P.; Costa, F.; Lennernas, B.; Linder, S.; Nilsson, S. Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines. Scand J Urol Nephrol 2009, 43, 98-103.
47. Karabulut, B.; Erten, C.; Gul, M. K.; Cengiz, E.; Karaca, B.; Kucukzeybek, Y.; Gorumlu, G.; Atmaca, H.; Uzunoglu, S.; Sanli, U. A.; Baran, Y.; Uslu, R. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int 2009, 33, 239-246.
48. Pickering, L. M.; Macdonald, C. D.; Coxon, J. P.; Mansi, J. L.; Colston, K. W. Zoledronic acid inhibits adhesion of breast cancer cells to protein matrices in a caspase dependent manner. Bone 2004, 34 (suppl 1, abstr 38), S68-S69
49. Garrioch, S.; Roelofs, A. J.; Ebetino, F. H.; Rogers, M. J. Prevention of breast cancer cell adhesion to bone in vitro by bisphosphonates is mediated by their inhibitory effect on protein prenylation. Bone 2006, 38 (3 suppl 1, abstr 45), S59-S60.
50. Boissier, S.; Ferreras, M.; Peyruchaud, O.; Magnetto, S.; Ebetino, F. H.; Colombel, M.; Delmas, P.; Delaissé, J. M.; Clézardin, P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000, 60, 2949-2954.
51. Koto, K.; Horie, N.; Kumura, S.; Murata, H.; Sakabe, T.; Matsui, T.; Watanabe, M.; Adachi, S.; Maekawa, T.; Fushiki, S.; Kubo, T. Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastases in a murine osteosarcoma model. Cancer Lett 2009, 274, 271-278.
52. Denoyelle, C.; Hong, L.; Vannier, J.-P.; Soria, J.; Soria, C. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by duel RhoA-dependent and-independent effects. Br J Cancer 2003, 88, 1631-1640.
53. Wood, J.; Bonjean, K.; Ruetz, S.; Bellahcène, A.; Devy, L.; Foidart, J. M.; Castronovo, V.; Green, J. R. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302, 1055-1061.
54. Yamada, J.; Tsuno, N. H.; Kitayama, J.; Tsuchiya, T.; Yoneyama, S.; Asakage, M.; Okaji, Y.; Shuno, Y.; Nishikawa, T.; Tanaka, J.; Takahashi, K.; Nagawa, H. Anti-angiogenic property of zoledronic acid by inhibition of endothelial progenitor cell differentiation. J Surg Res 2009, 151, 115-120.
55. Mantovani, A.; Schioppa, T.; Porta, C.; Allavena, P.; Sica, A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 2006, 25, 315-322.
56. Thompson, K.; Roelofs, A. J.; Jauhiainen, M.; Mönkkönen, H.; Mönkkönen, J.; Rogers, M. J. Activation of gammadelta T cells by bisphosphonates. Adv Exp Med Biol 2010, 658, 11-20.
57. Yuasa, T.; Kimura, S.; Ashihara, E.; Habuchi, T.; Maekawa, T. Zoledronic acid-a multiplicity of anti-cancer action. Curr Med Chem 2007, 14, 2126-2135.
58. Thompson, K.; Rogers, M. J. Statins prevent bisphosphonateinduced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004, 19, 278-288.
59. Dieli, F.; Gebbia, N.; Poccia, F.; Caccamo, N.; Montesano, C.; Fulfaro, F.; Arcara, C.; Valerio, M. R.; Meraviglia, S.; Di Sano, C.; Sireci, G.; Salerno, A. Induction of gamma, delta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 2003, 102, 2310-2311.
60. Li, W.; Yamamoto, H.; Kubo, S.; Okamura, H. Modulation of innate immunity by IL-18. J Reprod Immunol 2009, 83, 101-105.
61. Sato, K.; Kimura, S.; Segawa, H.; Yokota, A.; Matsumoto, S.; Kuroda, J.; Nogawa, M.; Yuasa, T.; Kiyono, Y.; Wada, H.; Maekawa, T. Cytotoxic effects of gamma, delta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 2005, 116, 94-99.
62. Coxon, F. P.; Thompson, K.; Roelofs, A. J.; Ebetino, F. H.; Rogers, M. J. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008, 42, 848-860.
63. Shih, J. Y.; Yuan, A.; Chen, J. J. W.; Yang, P. C. Tumor-associated macrophage: its role in cancer invasion and metastasis. J Cancer Mol 2006, 2, 101-106.
64. Daubiné, F.; Le Gall, C.; Gasser, J.; Green, J.; Clézardin, P. Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. J Natl Cancer Inst 2007, 99, 322-330.
65. Neville-Webbe, H. L.; Rostami-Hodjegan, A.; Evans, C. A.; Coleman, R. E.; Holen, I. Sequence-and schedule-dependent enhancement of zoledronic acid induced by apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer 2005, 113, 364-371.
66. Neville-Webbe, H. L.; Evans, C. A.; Coleman, R. E.; Holen, I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumor Biol 2006, 27, 92-103.
67. Neville-Webbe, H. L.; Coleman, R. E.; Holen, L. Combined effects of the bisphosphonate zoledronic acid and the aromatase inhibitor letrozole on breast cancer cells in vitro: evidence of synergistic interaction. Br J Cancer 2010, 102, 1010-1017.
68. Clyburn, R. D.; Reid, P.; Evans, C. A.; Lefley, D. V.; Holen, I. Increased anti-tumour effects of doxorubicin and zoledronic acid in prostate cancer cells in vitro: supporting the benefits of combination therapy. Cancer Chemother Pharmacol 2010, 65, 969-978.
69. Witters, L. M.; Crispino, J.; Fraterrigo, T.; Green, J.; Lipton, A. Effect of the combination of docetaxel, zoledronic acid, and a COX-2 inhibitor on the growth of human breast cancer cell lines. Am J Clin Oncol 2003, 26, S92-S97.
70. Vogt, U.; Bielawski, K. P.; Bosse, U.; Schlotter, C. M. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/ methotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 2004, 12, 1109-1114.
71. Melisi, D.; Caputo, R.; Damiano, V.; Bianco, R.; Veneziani, B. M.; Bianco, A. R.; De Placido, S.; Ciardiello, F.; Tortora, G. Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer. Endocr Relat Cancer 2005, 12, 1051-1058.
72. Ottewell, P. D.; Woodward, J. K.; Lefley, D. V.; Evans, C. A.; Coleman, R. E.; Holen, I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 2009, 8, 2821-2832.
73. Okamoto, K.; Tsurutani, J.; Terashima, M.; Okamoto, I.; Nakagawa, K. Zoledronic acid-induced regression of multiple metastases at nonskeletal sites. Ann Oncol 2009, 20796-797.
74. Laggner, U.; Lopez, J. S.; Perera, G.; Warbey, V. S.; Sita-Lumsden, A.; O'Doherty, M. J.; Hayday, A.; Harries, M.; Nestle, F. O. Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy. Clin Immunol 2009, 131, 367-373.
75. Español, I.; Romagosa, V.; Berlanga, J.; Domingo, A.; Losa, F.; Heras, L.; Janáriz, J. Zoledronate-induced remission of actue panmyelosis with myelofibrosis. Eur J Haematol 2004, 73, 215-218.
76. Rack, B.; Jückstock, J.; Genss, E. M.; Schoberth, A.; Schindlbeck, C.; Strobl, B.; Heinrigs, M.; Rammael, G.; Zwingers, T.; Sommer, H.; Friese, K.; Janni, W. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res 2010, 30(5):1807-1813.
77. Aft, R.; Naughton, M.; Trinkaus, K.; Watson, M.; Ylagan, L.; Chavez-MacGregor, M.; Zhai, J.; Kuo, S.; Shannon, W.; Diemer, K.; Hermann, V.; Dietz, J.; Ali, A.; Ellis, M.; Weiss, P.; Eberlein, T.; Ma, C.; Fracasso, P. M.; Zoberi, I.; Taylor, M.; Gillanders, W.; Pluard, T.; Mortimer, J.; Weilbaecher, K. Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol 2010, 11(5):421-428.
78. Greenberg, S.; Park, J. W.; Melisko, M. E.; Goga, A.; Moasser, M. M.; Anderson, M.; Scott, J. H.; Petrillo, L. A.; Moore, D. H.; Rugo, H. S. Effect of adjuvant zoledronic acid (ZOL) on disseminated tumor cells (DTC) in the bone marrow (BM) of women with early-stage breast cancer (ESBC): Updated results [abstract 1002]. Presented at the 46th American Society of Clinical Oncology Meeting, Chicago, IL, June 4-8, 2010.
79. Solomayer, E. F.; Gebauer, G.; Hirnle, P.; Janni, W.; Lück, H.-J.; Becker, S.; Huober, J.; Kraemer, B.; Wackwitz, B.; Fehm, T. Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients. Presented at the 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008 (abstr 2048).
80. γδ T cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 2009, 37, 956-968.
81. Santini, D.; Martini, F.; Fratto, M. E.; Galluzzo, S.; Vincenzi, B.; Agrati, C.; Turchi, F.; Piacentini, P.; Rocci, L.; Manavalan, J. S.; Tonini, G.; Poccia, F. In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients. Cancer Immunol Immunother 2009, 58, 31-38.
82. nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-13, 2009 (abstr 4083).
83. Brufsky, A.; Bosserman, L.; Caradonna, R.; Haley, B. B.; Jones, C. M.; Moore, H. C.; Jin, L.; Warsi, G. M.; Ericson, S. G.; Perez, E. A. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results. Clin Breast Cancer 2009, 9, 77-85.
84. Eidtmann, H.; de Boer, R.; Bundred, N.; Llombart-Cussac, A.; Davidson, N.; Neven, P.; von Micnkwitz, G.; Miller, J.; Schenk, N.; Coleman, R. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST Study. Ann Oncol 2010 May 5. [Epub ahead of print].
85. Brufsky, A.; Bundred, N.; Coleman, R.; Lambert-Falls, R.; Mena, R.; Hadji, P.; Jin, L.; Schenk, N.; Ericson, S.; Perez, E. A.; Z-FAST and ZO-FAST Study Groups. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 2008, 13, 503-514. (Pubitemid 351872868)
86. Frassoldati, A.; Brufsky, A.; Bundred, N.; Lambert-Falls, R.; Hadji, P.; Coleman, R. The effect of zoledronic acid on aromatase inhibitor (AI) associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant letrozole: 24 months (MOS) integrated follow-up of the Z-FAST/ZO-FAST trials. Ann Oncol 2008, 19 (suppl 8, abstr 185PD), viii78.
87. Coleman, R. E.; Winter, M. C.; Cameron, D.; Bell, R.; Dodwell, D.; Keane, M. M.; Gil, M.; Ritchie, D.; Passos-Coelho, J. L.; Wheatley, D.; Burkinshaw, R.; Marshall, S. J.; Thorpe, H. on behalf of the AZURE (BIG01/04) Investigators. The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response; exploratory revidence for direct anti-tumour activity in breast cancer. Br J Cancer 2010, 102, 1099-1105.
88. Winter, M. C.; Evans, A.; Holen, I.; Coleman, R. E. Anti-angiogenic potential of ZOL combined with neoadjuvant chemotherapy in invasive BC (ANZAC). Presented at the IX International Meeting on Cancer Induced Bone Disease, Arlington, VA, October 28-31, 2009 (abstr P67).
89. Scagliotti, G.; Manegold, C.; de Marinis, F.; Engel-Riedel, W.; Albert, I.; Sallo, V.; Chen, Y. M.; Perez, J. R.; Kosmidis, P. Evaluating the efficacy of zoledronic acid for the prevention of disease progression in patients with non-small cell lung cancer. Presented at the joint 15th Congress of the European Cancer Organisation and 34th Congress of the European Society for Medical Oncology, Berlin, Germany, September 20-24, 2009 (abstr P-9056).
90. ClinicalTrials.gov. Clinical Trials. Gov List Results. http://clinicaltrials.gov/ct2/results?intr=%22zoledronic+acid%22. Accessed August 26, 2010.
91. Morgan, G.; Davies, F.; Gregory, W.; Bell, S. E.; Szubert, A.; Navarro Coy, N.; Drayson, M.; Owen, R. G.; Jackson, G. H.; Child, J. A. Evaluating the effects of zoledronic acid (ZOL) on overall survival (OS) in patients (Pts) with multiple myeloma (MM): Results of the Medical Research Council (MRC) Myeloma IX study [abstract 8021]. Presented at: 46th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, June 4-8, 2010